Aducanumab Early Alzheimer's Disease Study

ClinicalTrials.gov registered a new clinical trial for aducanumab, an amyloid-targeting monoclonal antibody, in early Alzheimer's disease. The registry entry provides study design parameters, participant eligibility criteria, and outcome measures. No regulatory obligations are created by this registration.

For pharmaceutical companies and clinical investigators, this registry entry documents an ongoing drug development program in Alzheimer's disease. Sponsors conducting similar Alzheimer's trials should ensure their own studies are properly registered on ClinicalTrials.gov in accordance with applicable requirements.